Claims for Patent: 9,771,418

Summary for Patent: 9,771,418

Title:	Methods for treating complement-associated disorders
Abstract:	The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
Inventor(s):	Rother; Russell P. (Oklahoma City, OK), Bedrosian; Camille (Woodbridge, CT), Squinto; Stephen P. (Bethany, CT), Bell; Leonard (Woodbridge, CT)
Assignee:	Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:	15/243,290
Patent Claims:	1. A method for treating antibody-mediated rejection (AMR) in a patient having a kidney transplant, the method comprising intravenously administering to the patient: 1200 mg of eculizumab less than 24 hours before or during the transplant operation and one post-operative dose of eculizumab within 24 hours of the transplant operation; 900 mg of eculizumab once a week for four weeks after the post-operative dose; and 1200 mg of eculizumab on week five after the post-operative dose and bi-weekly thereafter. 2. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain at least 50 .mu.g of eculizumab per milliliter of the patient's blood. 3. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain at least 100 .mu.g of eculizumab per milliliter of the patient's blood. 4. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain a concentration of at least 0.7 molecules of eculizumab per every C5 molecule in the patient's blood.

Details for Patent 9,771,418

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	03/16/2007		2028-11-10